echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > The new method of dosing is expected to reduce the rate of cancer recurrence

    The new method of dosing is expected to reduce the rate of cancer recurrence

    • Last Update: 2020-12-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A U.S. research team has developed a new way to deliver chemotherapy and immunotherapy drugs to the tumor site by injecting special gels, promising to reduce the rate of cancer recurrence.
    the study, the University of North Carolina team treated melanoma and a breast cancer previously less sensitive to immunotherapy based on animal models. The results showed that after the primary tumor was removed in mice, the therapy significantly reduced the recurrence rate of cancer. The study was published recently in
    American Journal.
    researchers say bio-compatible polymers can be mixed with crosslinkers to form gels in the body immediately, carrying the chemotherapy drug gisectabin and an immunochemical checkpoint inhibitor.
    explained that the gel first increases the concentration of reactive oxygen that accompanies tumor growth, allowing immunotherapy drugs to better identify tumors. The concentration of reactive oxygen causes the gel to melt gradually and releases two drugs in a series. Chemotherapy drugs kill some cancer cells first, increasing the sensitivity of tumors to immunotherapy drugs. As the gel degrades, the reactive oxygen levels at the tumor site decrease, which helps inhibit tumor growth.
    "It's an easy way to pry the biological characteristics of tumors and the body's autoimmune system at the same time as chemotherapy to inhibit tumor development and reduce side effects," gu Wei, an associate professor at the University of North Carolina at Chapel Hill and author of the paper, told the media. "
    that this approach may also be effective for other tumors," he said. There's still a lot of work to be done before we go into clinical trials, but I think this approach is promising. Gu said. (Source: Xinhua News Agency Zhou Zhou)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.